These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. Models of Gastroenteropancreatic Neuroendocrine Neoplasms: Current Status and Future Directions. Detjen K; Hammerich L; Özdirik B; Demir M; Wiedenmann B; Tacke F; Jann H; Roderburg C Neuroendocrinology; 2021; 111(3):217-236. PubMed ID: 32615560 [TBL] [Abstract][Full Text] [Related]
10. APOBEC3B High Expression in Gastroenteropancreatic Neuroendocrine Neoplasms and Association With Lymph Metastasis. Feng C; Zheng Q; Yang Y; Xu M; Lian Y; Huang J; Jiang Y Appl Immunohistochem Mol Morphol; 2019 Sep; 27(8):599-605. PubMed ID: 30095460 [TBL] [Abstract][Full Text] [Related]
11. Variability of the Ki-67 proliferation index in gastroenteropancreatic neuroendocrine neoplasms - a single-center retrospective study. Shi H; Zhang Q; Han C; Zhen D; Lin R BMC Endocr Disord; 2018 Jul; 18(1):51. PubMed ID: 30055596 [TBL] [Abstract][Full Text] [Related]
12. Glutaminases in slowly proliferating gastroenteropancreatic neuroendocrine neoplasms/tumors (GEP-NETs): Selective overexpression of mRNA coding for the KGA isoform. Szeliga M; Ćwikła J; Obara-Michlewska M; Cichocki A; Albrecht J Exp Mol Pathol; 2016 Feb; 100(1):74-8. PubMed ID: 26581715 [TBL] [Abstract][Full Text] [Related]
13. Analysis of 320 gastroenteropancreatic neuroendocrine tumors identifies TS expression as independent biomarker for survival. Lee HS; Chen M; Kim JH; Kim WH; Ahn S; Maeng K; Allegra CJ; Kaye FJ; Hochwald SN; Zajac-Kaye M Int J Cancer; 2014 Jul; 135(1):128-37. PubMed ID: 24347111 [TBL] [Abstract][Full Text] [Related]
14. Inhibition of mTOR's Catalytic Site by PKI-587 Is a Promising Therapeutic Option for Gastroenteropancreatic Neuroendocrine Tumor Disease. Freitag H; Christen F; Lewens F; Grass I; Briest F; Iwaszkiewicz S; Siegmund B; Grabowski P Neuroendocrinology; 2017; 105(1):90-104. PubMed ID: 27513674 [TBL] [Abstract][Full Text] [Related]
15. Novel preclinical gastroenteropancreatic neuroendocrine neoplasia models demonstrate the feasibility of mutation-based targeted therapy. Viol F; Sipos B; Fahl M; Clauditz TS; Amin T; Kriegs M; Nieser M; Izbicki JR; Huber S; Lohse AW; Schrader J Cell Oncol (Dordr); 2022 Dec; 45(6):1401-1419. PubMed ID: 36269546 [TBL] [Abstract][Full Text] [Related]
16. Heterogeneity of grade 3 gastroenteropancreatic neuroendocrine carcinomas: New insights and treatment implications. Fazio N; Milione M Cancer Treat Rev; 2016 Nov; 50():61-67. PubMed ID: 27636009 [TBL] [Abstract][Full Text] [Related]
17. Role of PD-L1 expression as a biomarker for GEP neuroendocrine neoplasm grading. Cavalcanti E; Armentano R; Valentini AM; Chieppa M; Caruso ML Cell Death Dis; 2017 Aug; 8(8):e3004. PubMed ID: 28837143 [TBL] [Abstract][Full Text] [Related]
18. Serotonin and the 5-HT7 receptor: the link between hepatocytes, IGF-1 and small intestinal neuroendocrine tumors. Svejda B; Kidd M; Timberlake A; Harry K; Kazberouk A; Schimmack S; Lawrence B; Pfragner R; Modlin IM Cancer Sci; 2013 Jul; 104(7):844-55. PubMed ID: 23578138 [TBL] [Abstract][Full Text] [Related]
19. The Clinical Significance of PD-L1/PD-1 Expression in Gastroenteropancreatic Neuroendocrine Neoplasia. Wang C; Yu J; Fan Y; Ma K; Ning J; Hu Y; Niu W; Dong X; Wu Y; Li E; Dong D Ann Clin Lab Sci; 2019 Sep; 49(4):448-456. PubMed ID: 31471333 [TBL] [Abstract][Full Text] [Related]
20. The clinical implications and biologic relevance of neurofilament expression in gastroenteropancreatic neuroendocrine neoplasms. Schimmack S; Lawrence B; Svejda B; Alaimo D; Schmitz-Winnenthal H; Fischer L; Büchler MW; Kidd M; Modlin I Cancer; 2012 May; 118(10):2763-75. PubMed ID: 21990041 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]